Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck pharmaceutical Segment — Segment Profit / Pretax Income ($M) ($M)
Postgres DB segment_values
Latest, Q2 2026
11,612
Period ended Jun 30, 2026
Change on a year earlier
+4.6%
11,103 in Q2 2025
History
52 quarters
Since Q1 2013
Sources
40
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pharmaceutical Segment — Segment Profit / Pretax Income ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 11,612 | +4.6% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 11,519 | +7.5% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 11,490 | +5.6% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 12,538 | +8.6% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 11,103 | -0.9% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 10,712 | -1.8% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 10,882 | +14.8% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2024 | Sep 30, 2024 | 11,547 | +11.0% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 11,200 | +13.7% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 10,904 | +19.3% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 9,480 | +10.4% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 10,407 | +8.5% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 9,854 | +7.4% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 9,140 | -3.8% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 8,589 | +0.7% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2022 | Sep 30, 2022 | 9,590 | +11.4% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 9,173 | +26.4% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 9,501 | +44.2% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 8,527 | +24.1% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2021 | Sep 30, 2021 | 8,606 | +22.5% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2021 | Jun 30, 2021 | 7,257 | +24.4% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2021 | Mar 31, 2021 | 6,589 | -13.1% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 6,871 | +241.7% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 7,026 | -9.3% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 5,832 | -18.0% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2020 | Mar 31, 2020 | 7,582 | +15.3% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2019 | Dec 31, 2019 | 2,011 | -68.3% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 7,747 | +17.0% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 7,115 | +19.1% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 6,574 | +10.7% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 6,336 | -0.4% | Form 10-K (filed 2020-02-26) ↗ |
| Q3 2018 | Sep 30, 2018 | 6,621 | +12.1% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 5,975 | +6.9% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 5,939 | +15.1% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 6,361 | +16.9% | Form 10-K (filed 2020-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 5,906 | -4.2% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 5,590 | +3.1% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 5,160 | +0.8% | Form 10-Q (filed 2018-05-08) ↗ |
| Q4 2016 | Dec 31, 2016 | 5,443 | -2.3% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2016 | Sep 30, 2016 | 6,162 | +9.2% | SEC Filing ↗ |
| Q2 2016 | Jun 30, 2016 | 5,420 | +2.6% | SEC Filing ↗ |
| Q1 2016 | Mar 31, 2016 | 5,117 | -0.9% | SEC Filing ↗ |
| Q4 2015 | Dec 31, 2015 | 5,570 | -2.1% | Form 10-K (filed 2016-02-26) ↗ |
| Q3 2015 | Sep 30, 2015 | 5,641 | -2.3% | Form 10-Q (filed 2015-11-05) ↗ |
| Q2 2015 | Jun 30, 2015 | 5,282 | -4.1% | Form 10-Q (filed 2015-08-06) ↗ |
| Q1 2015 | Mar 31, 2015 | 5,165 | -0.6% | Form 10-Q (filed 2015-05-07) ↗ |
| Q4 2014 | Dec 31, 2014 | 5,689 | – | Form 10-K (filed 2015-02-27) ↗ |
| Q3 2014 | Sep 30, 2014 | 5,772 | -3.5% | Form 10-Q (filed 2014-11-10) ↗ |
| Q2 2014 | Jun 30, 2014 | 5,507 | – | Form 10-Q (filed 2014-08-07) ↗ |
| Q1 2014 | Mar 31, 2014 | 5,197 | -2.8% | Form 10-Q (filed 2014-05-08) ↗ |
| Q2 2013 | Sep 30, 2013 | 5,983 | – | Form 10-Q (filed 2014-11-10) ↗ |
| Q1 2013 | Mar 31, 2013 | 5,345 | – | Form 10-Q (filed 2014-05-08) ↗ |
Cite this data
StockData. (2026). Merck Pharmaceutical Segment — Segment Profit / Pretax Income ($M) ($M), quarterly Q1 2013–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db_seg_pharma_pretax
See every metric in the Merck KPI table. Data updated Oct 26, 2026.